Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, B-Cell 2Leukemia 2Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Hematologic Neoplasms 1

Interventions

Peripheral Blood Stem Cell Transplantation 39fludarabine phosphate 36Cyclophosphamide 31Mycophenolic Acid 28Cyclosporine 25Whole-Body Irradiation 24Tacrolimus 22Busulfan 18Antilymphocyte Serum 18Radiotherapy 16Methotrexate 16Flow Cytometry 14Filgrastim 14Etoposide 13Methylprednisolone 10Lenalidomide 10Bortezomib 10Vorinostat 9Melphalan 9mogamulizumab 8Therapeutics 8Rituximab 8Psychiatric Rehabilitation 8Polymerase Chain Reaction 8Gemcitabine 8Cord Blood Stem Cell Transplantation 7Bexarotene 7pembrolizumab 6Alemtuzumab 6tanespimycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sezary Syndrome × navitoclax × Lymphoid × Clear all
NCT00406809 2021-08-02

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

AbbVie

Phase 1/2 Completed
81 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Leukemia, B-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡